2020-12-02
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read the full press release: https://www.camurus.com/
2023-05-23
Are you a recent engineering graduate eager to learn more and to develop your personal skills?
Read more2023-05-10
Camurus' Interim Report for the first quarter 2023, which was published today, showed a strong quarter with solid or…
Read more2023-05-04
Last year's book are closed and we have put the first quarter of 2023 behind us. 2022 was characterized by a range o…
Read more2023-02-15
Camurus' Full Year Report for 2022 was published on February 14. 2022 was the first profitable year for Camurus, dri…
Read more2023-02-10
Sandberg Development has donated a large sum to UNICEF to support them in their work to help families and children…
Read more